Table 3.

The association of KRAS and all gene (KRAS, BRAF, NRAS, PIK3CA) mutations with clinical and pathological characteristics

Characteristic	N	KRAS			All genes
		MT	WT	P	MT	WT	P
Total	55	37	18		39	16
Age
<65	29	20	9	1.000	22	7	0.393
≥65	26	17	9		17	9
Gender
Female	26	20	6	0.166	20	6	0.352
Male	29	17	12		19	10
Location
C18-19	35	25	10	0.358	26	9	0.466
C20	20	12	8		13	7
Side
Right	12	10	2	0.289	10	2	0.284
Left	43	27	16		29	14
Type of adenocarcinoma
Adenocarcinoma	44	26	18	0.010	28	16	0.023
Mucinous	11	11	0		11	0
Tumour budding
Yes	21	15	6	0.606	16	5	0.498
No	34	22	12		23	11
Extrahepatic metastases
Yes	34	23	11	0.938	25	9	0.586
No	21	14	7		14	7
Lung metastases
Yes	20	13	7	0.786	15	5	0.614
No	35	24	11		24	11
Peritoneal metastases
Yes	8	5	3	0.756	6	2	0.783
No	47	32	15		33	14
Lymphnode metastases
Yes	12	7	5	0.455	8	4	0.714
No	43	30	13		31	12
Treatment arm
FOLFOX4	26	19	7	0.389	19	7	0.738
FOLFOX4 + bevacizumab	29	18	11		20	9